Description
Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. The Company’s CD19 product candidates include JCAR015, JCAR017, and JCAR014. Its additional product candidates include CD22, L1CAM, MUC-16/IL-12, ROR-1 and WT-1.
Address
307 Westlake Ave N Ste 300
SEATTLE, WA 98109-5235
United States
SEATTLE, WA 98109-5235
United States
Website
http://junotherapeutics.comKey stats and ratios
| Q3 (Sep '14) | 2013 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -48.60% | - |
| Return on average equity | - | - |
| Employees | 70 |
No comments:
Post a Comment